Robert Hazlett
Stock Analyst at BTIG
(1.29)
# 3,641
Out of 5,042 analysts
23
Total ratings
39.13%
Success rate
-1.45%
Average return
Main Sectors:
Stocks Rated by Robert Hazlett
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| AURA Aura Biosciences | Maintains: Buy | $21 → $24 | $5.86 | +309.56% | 3 | Oct 18, 2024 | |
| NKTR Nektar Therapeutics | Assumes: Buy | $60 | $60.10 | -0.17% | 2 | Sep 30, 2024 | |
| RANI Rani Therapeutics Holdings | Maintains: Buy | $7 → $14 | $1.82 | +669.23% | 2 | May 9, 2024 | |
| LYRA Lyra Therapeutics | Maintains: Buy | $1,200 → $1,000 | $6.37 | +15,599.08% | 1 | Feb 7, 2023 | |
| AXSM Axsome Therapeutics | Maintains: Buy | $62 → $98 | $129.55 | -24.35% | 2 | Dec 23, 2022 | |
| VSTM Verastem | Maintains: Buy | $96 → $60 | $7.95 | +654.72% | 3 | Oct 5, 2022 | |
| CMPS COMPASS Pathways | Initiates: Buy | $63 | $6.28 | +903.18% | 1 | May 27, 2021 | |
| PRTA Prothena Corporation | Upgrades: Buy | $29 | $9.82 | +195.32% | 4 | Feb 2, 2021 | |
| RDHL RedHill Biopharma | Initiates: Buy | $26,000 | $1.64 | +1,585,265.85% | 1 | Sep 11, 2020 | |
| AKBA Akebia Therapeutics | Maintains: Buy | $26 → $6 | $3.03 | +98.02% | 2 | Sep 4, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $18 | $11.13 | +61.73% | 2 | Aug 31, 2017 |
Aura Biosciences
Oct 18, 2024
Maintains: Buy
Price Target: $21 → $24
Current: $5.86
Upside: +309.56%
Nektar Therapeutics
Sep 30, 2024
Assumes: Buy
Price Target: $60
Current: $60.10
Upside: -0.17%
Rani Therapeutics Holdings
May 9, 2024
Maintains: Buy
Price Target: $7 → $14
Current: $1.82
Upside: +669.23%
Lyra Therapeutics
Feb 7, 2023
Maintains: Buy
Price Target: $1,200 → $1,000
Current: $6.37
Upside: +15,599.08%
Axsome Therapeutics
Dec 23, 2022
Maintains: Buy
Price Target: $62 → $98
Current: $129.55
Upside: -24.35%
Verastem
Oct 5, 2022
Maintains: Buy
Price Target: $96 → $60
Current: $7.95
Upside: +654.72%
COMPASS Pathways
May 27, 2021
Initiates: Buy
Price Target: $63
Current: $6.28
Upside: +903.18%
Prothena Corporation
Feb 2, 2021
Upgrades: Buy
Price Target: $29
Current: $9.82
Upside: +195.32%
RedHill Biopharma
Sep 11, 2020
Initiates: Buy
Price Target: $26,000
Current: $1.64
Upside: +1,585,265.85%
Akebia Therapeutics
Sep 4, 2020
Maintains: Buy
Price Target: $26 → $6
Current: $3.03
Upside: +98.02%
Aug 31, 2017
Initiates: Buy
Price Target: $18
Current: $11.13
Upside: +61.73%